The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non-small cell lung cancer
机构：[1]Department of Pulmonary and Critical Care Medicine State Key Laboratory of Respiratory Health and Multimorbidity West China Hospital of Sichuan University, Precision Medicine Key Laboratory of Sichuan Province Chengdu Sichuan China.[2]Lung Cancer Center/Lung Cancer Institute West China Hospital, Sichuan University Chengdu Sichuan China.[3]Geneplus-Beijing Institute Beijing China.[4]Departments of Bioinformatics and Computational Biology University of Texas MD Anderson Cancer Center Houston Texas USA.[5]Department of Thoracic/Head and Neck Medical Oncology University of Texas MD Anderson Cancer Center Houston Texas USA.[6]Department of Pulmonary and Critical Care Medicine West China Hospital, West China School of Medicine, Sichuan University Chengdu Sichuan China.四川大学华西医院[7]Department of Genomic Medicine University of Texas MD Anderson Cancer Center Houston Texas USA.[8]Lung Cancer Genomics Program University of Texas MD Anderson Cancer Center Houston Texas USA.[9]Lung Cancer Interception Program University of Texas MD Anderson Cancer Center Houston Texas USA.
National Natural Science Foundation of
China, Grant/Award Numbers: 82072598,
92159302; 1-3-5 project for disciplines of
excellence,West China Hospital, Sichuan
University, China, Grant/Award
Numbers: ZYJC21052, ZYGD22009;
Science and Technology Project of
Sichuan, China, Grant/Award Number:
2022ZDZX0018
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类|3 区医学
小类|3 区医学：研究与实验
第一作者：
第一作者机构：[1]Department of Pulmonary and Critical Care Medicine State Key Laboratory of Respiratory Health and Multimorbidity West China Hospital of Sichuan University, Precision Medicine Key Laboratory of Sichuan Province Chengdu Sichuan China.[2]Lung Cancer Center/Lung Cancer Institute West China Hospital, Sichuan University Chengdu Sichuan China.
通讯作者：
通讯机构：[1]Department of Pulmonary and Critical Care Medicine State Key Laboratory of Respiratory Health and Multimorbidity West China Hospital of Sichuan University, Precision Medicine Key Laboratory of Sichuan Province Chengdu Sichuan China.[2]Lung Cancer Center/Lung Cancer Institute West China Hospital, Sichuan University Chengdu Sichuan China.[5]Department of Thoracic/Head and Neck Medical Oncology University of Texas MD Anderson Cancer Center Houston Texas USA.[7]Department of Genomic Medicine University of Texas MD Anderson Cancer Center Houston Texas USA.[8]Lung Cancer Genomics Program University of Texas MD Anderson Cancer Center Houston Texas USA.[9]Lung Cancer Interception Program University of Texas MD Anderson Cancer Center Houston Texas USA.[*1]Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China[*2]Department of Thoracic/Head and Neck Medical Oncology, Department of Genomic Medicine, Lung Cancer Genomics Program, Lung Cancer Interception Program, University of Texas MD Anderson Cancer Center, Houston/United States of America, Houston, TX 77030, USA.
推荐引用方式(GB/T 7714)：
Li Yalun,Ji Liyan,Zhang Yingqian,et al.The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non-small cell lung cancer[J].Medcomm.2024,5(6):e604.doi:10.1002/mco2.604.
APA：
Li Yalun,Ji Liyan,Zhang Yingqian,Zhang Jiexin,Reuben Alexandre...&Tian Panwen.(2024).The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non-small cell lung cancer.Medcomm,5,(6)
MLA：
Li Yalun,et al."The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non-small cell lung cancer".Medcomm 5..6(2024):e604
